|Tested species reactivity||Human|
|Host / Isotype||Sheep / IgG|
|Immunogen||Human Factor XII.|
|Purification||Ammonium sulfate precipitation, Ion-exchange chromatography|
|Storage buffer||50% water with 50% glycerol|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|ELISA (ELISA)||5-10 µg/mL|
|Western Blot (WB)||5-10 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA1-43049 detects Factor XII in human samples.
PA1-43049 has successfully been used in Western blot and ELISA applications.
PA1-43049 was derived from human factor XII.
This single chain zymogen is converted to a two-chain serine protease with an heavy chain (alpha-factor XIIa) and a light chain. The heavy chain contains two fibronectin-type domains, two epidermal growth factor (EGF)-like domains, a kringle domain and a proline-rich domain, whereas the light chain contains only a catalytic domain. On activation, further cleavages takes place in the heavy chain, resulting in the production of beta-factor XIIa light chain and the alpha-factor XIIa light chain becomes beta-factor XIIa heavy chain. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then to beta-factor XIIa. The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI. Defects in this gene do not cause any clinical symptoms and the sole effect is that whole-blood clotting time is prolonged.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.